Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma.

ABSTRACT:

Background

Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality in women. In this study, we evaluated the expression of human fibroblast growth factor 23 (FGF23) in different US subtypes and the relationship between survival and clinicopathological characteristics.

Methods

We conducted a comparative analysis of FGF23 gene expression in different pathological types of US. Utilizing a cohort from The Cancer Genome Atlas of 57 patients, a 50-patient microarray dataset (GSE119043) from the Gene Expression Omnibus and a Suining cohort of 44 patients, we analyzed gene expression profiles and corresponding clinicopathological information. Immunohistochemistry was used to examine the expression level of FGF23 in four US subtypes. Survival analysis

SUBMITTER: Yang L 

PROVIDER: S-EPMC11015760 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature